PeerView CME Symposium

Expanding Frontline Frontiers in MM: Insights on Delivering Modern Care With Innovative CD38 Quadruplet Platforms

Saturday, May 25th – 16:30-17:30 CEST


Chair & Moderator
Prof. Mohamad Mohty, MD, PhD
Professor of Hematology
Hematology and Cellular Therapy Department
Saint-Antoine Hospital
Sorbonne University
Paris, France

Professor Thierry Facon, MD
Professor of Haematology, Department of Haematology
Lille University Hospital
Lille, France

Joshua Richter, MD
Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
Director of Myeloma
Blavatnik Family Chelsea Medical Center at Mount Sinai
New York, New York

Activity Description

Although outcomes have improved for patients with multiple myeloma (MM), this disease remains a challenging condition, placing a considerable burden on patients and requiring judicious selection of upfront and sequential therapy on the part of clinicians. A growing body of evidence and clinical experience from both the European Union and the United States now supports the rapid integration of CD38 antibody quadruplet regimens in newly diagnosed MM (NDMM)–a development with implications for first-line and successive lines of therapy.

In this CME-certified PeerView Live “Clinical Consults” symposium held during the 2024 COMy Congress in Paris, France, leading MM specialists will use a series of conversational, case-based discussions to share their clinical experiences and provide valuable insights on crafting proactive upfront treatment with antibody-based quadruplets while offering guidance on dosing, scheduling, and safety considerations in transplant-eligible and ineligible patients. Don’t forget to sign up early and join us at COMy 2024 for this exciting event! Sign up today:


This activity is supported by an educational grant from Sanofi.


16:30 CEST: Symposium

Pre-Consult Prep: Current Standards and Ongoing Challenges in NDMM

Clinical Consult Sessions

  • Deploying CD38 Quadruplet Strategies in Transplant-Eligible NDMM
  • Extending Innovation With CD38 Quadruplets in Transplant-Ineligible NDMM

Symposium Summary and Q&A

17:30 CEST: Adjourn